Inclusion Criteria:

1. Histologic diagnosis of carcinoma of the prostate within 6 months of entry without
evidence of metastatic disease to the lymph nodes, bone or lung;

2. Intermediate risk prostate cancer (that is, T1-2a, Gleason score <6, PSA 10.1-20.0
ng/ml; T2b-c Gleason <6, PSA ≤ 20.0 ng/ml; T1-2, Gleason 7, PSA ≤ 20.0 ng/ml).

Exclusion Criteria:

1. Histologic diagnosis of carcinoma of the prostate more than six months prior to study
entry;

2. Previous therapy for carcinoma of the prostate other than biopsy or transurethral
resection;

3. Patients previously on more than 12 weeks of hormone therapy for treatment of their
prostate cancer;

4. Any other active malignancy (untreated, progressive or recurrent), except for
non-melanoma skin cancer. Any inactive malignancy diagnosed within 5 years of entry,
except for non-melanoma skin cancer;

5. Treatment plan cannot meet dose constraints for the hypofractionation arm of the
trial;

6. Previous pelvic radiotherapy;

7. Inflammatory bowel disease.